The innovative CoolCryo® system for cardiac cryoablation, for which Biostat is conducting a clinical trial, has been successfully used for the first time during cardiac surgery.

In 2023, we reported that Biostat's Research and Development Center will conduct a clinical trial of the CoolCryo® medical device, which was developed by Medinice, a Polish company specializing in innovative solutions for cardiology and cardiac surgery.

CoolCryo® is an innovative system for cardiac cryoablation using liquid nitrogen as a cooling medium. Liquid nitrogen is not only widely available, but also the cheapest, compared to the gases used in available cryoablation systems, significantly reducing the cost of the procedure. Thanks to this solution, cryoablation performed with the CoolCryo® system more precisely eliminates the areas of myocardial tissue responsible for cardiac disorders.

On July 4 this year, Medinice announced that the first cardiac surgery was carried out, during which cryoablation was performed using the investigational CoolCryo® system. The operation took place at the Silesian Center for Heart Diseases in Zabrze, where the study is being conducted under the direction of Tomasz Hrapkowicz, MD.

- The first patient treatment with the CoolCryo system represents a momentous achievement! Our breakthrough technology has the potential to revolutionize the treatment of arrhythmias, offering surgeons a faster and more effective therapeutic option for patients,

comments Grzegorz Wroblewski PhD - Chief Technology Officer at Medinice S.A.

The doctors' success opens up a wide range of possibilities for Medinice to commercialize the CoolCryo system.

- We are all in good spirits and keep our fingers crossed for the health of the patients who take part in the study! Clinical confirmation of the safety and effectiveness of our system opens up the possibility of profitable commercialization, a project that has been under development for many years,"

stresses Sanjeev Choudhary one of the originators of the project and CEO of Medinice S.A.

Rafal Piszczek - CEO of Biostat - does not hide his satisfaction with the cooperation with Medinice in the clinical trial of the CoolCryo system.

- This project perfectly fits into our mission, which is the transfer of science to business. I am convinced that the CoolCryo system will make a great contribution to the development of cardiac surgery, and for Medinice it will end in a spectacular commercial success,"

comments Rafal Piszczek.

>Read more: Biostat. Full-service CRO